Haisco's HSK60002 Tablet Wins NMPA Clinical Trial Approval for Inflammatory Diseases
Haisco announced on August 12, 2026 that it received a Clinical Trial Approval Notice from China's National Medical Products Administration for its HSK60002 tablet, a class 1 innovative chemical drug. The oral small-molecule formulation is intended for treating inflammatory diseases. Preclinical studies showed significant efficacy in animal models with a clear mechanism of action. The company will proceed with further research as planned.
Haisco announced on August 12, 2026 that it recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for HSK60002 tablets, granting permission to conduct clinical trials for the drug. HSK60002 is a class 1 innovative chemical drug, an oral small-molecule formulation intended for the treatment of inflammatory diseases.
The announcement stated that the drug was independently developed by the company. Preclinical study data showed significant pharmacological activity in relevant animal models, with a clear mechanism of action. Having now obtained clinical trial approval, the company will advance related research work as planned.